Takara Holdings' Takara Bio Transfers Cell Processing Contract Manufacturing Business to S-RACMO

Bitget2026/11/02 04:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Takara Holdings' subsidiary Takara Bio will transfer its GMP cell processing contract manufacturing business to S-RACMO effective Jan. 1, 2027.
The company split aims to improve CDMO profitability by concentrating resources on priority manufacturing businesses.
The restructuring includes workforce reductions, employment opportunities for affected staff and sales of related facilities and equipment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takara Holdings Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Takara Holdings' Takara Bio Transfers Cell Processing Contract Manufacturing Business to S-RACMO

You may also like

Crypto prices